Celldex Therapeutics (NASDAQ: CLDX) Price Target Soars on Positive Phase III Clinical Trial Results

• Leerink Partners significantly raised its price target for Celldex Therapeutics to $88.00, indicating strong analyst confidence in the biotechnology stock.
• Celldex reported successful Phase III clinical trial results for its drug barzolvolimab in treating chronic spontaneous urticaria (CSU), meeting all primary endpoints.
• Despite the positive news regarding CSU, the Celldex stock price experienced a slight decline following the discontinuation of a separate Phase 2 trial for barzolvolimab in another condition.

Celldex Therapeutics (NASDAQ: CLDX) is a leading biotechnology stock that develops innovative therapies to treat specific diseases. With a market capitalization of around $2.1 billion, the company focuses on creating targeted treatments through advanced drug development. Its main drug candidate is barzolvolimab, which is being studied for several conditions.

On September 23, 2026, Thomas Smith of Leerink Partners increased the price target for Celldex Therapeutics to $88.00 from $70.00. A price target is an analyst's projection of a stock's future price, crucial for stock analysis. At the time, the stock was trading at $31.19, showing significant potential upside according to the analyst.

This optimism follows positive results from Celldex's Phase III clinical trials for barzolvolimab. The drug is designed for adults with chronic spontaneous urticaria (CSU), a skin condition, who do not get better with antihistamines. The studies, EMBARQ-CSU1 and EMBARQ-CSU2, met all their main goals, highlighting progress in CSU treatment.

The trials showed that barzolvolimab was effective and that its benefits lasted or even improved over 24 weeks. As highlighted by Defense World, these global trials included 1,939 patients. Celldex now plans to submit a Biologics License Application (BLA) in 2027, a key step towards potential FDA approval for the new drug.

However, as reported by Benzinga, Celldex also stopped a separate Phase 2 trial of barzolvolimab for a different condition after it failed to meet its goals. Despite the positive CSU news, the Celldex stock price decreased by 6.03% to $31.49 during the day's trading.